Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IL-7 R alpha

IL-7 R alpha

Brief Information

Name:Interleukin-7 receptor subunit alpha
Target Synonym:Interleukin-7 receptor subunit alpha,Interleukin 7 Receptor Isoform H5-6,CDw127,IL-7R subunit alpha,IL-7RA,IL-7 receptor subunit alpha,CD127 Antigen,IL-7R-Alpha,Interleukin 7 Receptor Alpha Chain,CD127,IL7RA,ILRA,Interleukin-7 Receptor alpha Subunit
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:9
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

 IL-7 R alpha SPR

Captured Human IL-7 R alpha, Mouse IgG2a Fc Tag (Cat. No. IL7-H5258) on CM5 chip via anti-mouse antibodies surface can bind ActiveMax® Human IL-7, Tag Free (Cat. No. IL7-H4219) with an affinity constant of 13.3 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

 IL-7 R alpha ELISA

Immobilized Human IL-7, Fc Tag (Cat. No. IL7-H5253) at 2 μg/mL (100 μL/well) can bind Biotinylated Human IL-7 R alpha Protein, Fc,Avitag (Cat. No. IL7-H82F9) with a linear range of 1-20 ng/mL (QC tested).

Synonym Name



Interleukin-7 receptor subunit alpha (IL7Ra) is also known as CD antigen CD127, which belongs to the type I cytokine receptor family and type 4 subfamily. IL7Ra /CD127 contains 1 fibronectin type-III domain. IL7Ra /CD127 is expressed on various cell types, including naive and memory T cells and many others. IL7Ra /CD127 is receptor for interleukin-7 and also acts as a receptor for thymic stromal lymphopoietin (TSLP). The IL7 receptor is a heterodimer of IL7R and IL2RG. The TSLP receptor is a heterodimer of CRLF2 and IL7R.

Clinical and Translational Updates

Related Molecule

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Interleukin-7 (Revimmune SAS) rhIL-7; CYT-107; CYT-99-007 Phase 2 Clinical Cytheris Urinary Bladder Neoplasms; Catheter-Related Infections; Neuroectodermal Tumors, Primitive, Peripheral; Melanoma; T-Lymphocytopenia, Idiopathic CD4-Positive; Leukemia, Myeloid, Acute; Urologic Neoplasms; Ureteral Neoplasms; Hepatitis C; Lymphopenia; Urethral Neoplasms; Prostatic Neoplasms; Sarcoma; Neuroblastoma; Shock, Septic; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Transitional Cell; Sepsis; Myeloproliferative Disorders; Myelodysplastic Syndromes; Mycobacterium Infections, Nontuberculous; Coronavirus Disease 2019 (COVID-19); Carcinoma, Renal Cell; Hepatitis B, Chronic; Rhabdoid Tumor; Leukemia, Myelogenous, Chronic; Kidney Neoplasms; HIV Infections Details
Lusvertikimab OSE-127; S-95011; Effi-7; OSE-217 Phase 2 Clinical Effimune Sjogren's Syndrome; Colitis, Ulcerative Details
MDK-703 MDK-703 Phase 2 Clinical Medikine Inc Solid tumours Details
Efineptakin alfa TJ-107; GX-I7; NT-I7 Phase 2 Clinical Genexine Inc Breast Neoplasms; Sarcoma, Kaposi; Melanoma; Carcinoma, Non-Small-Cell Lung; Glioma; Laryngeal Neoplasms; Leukoencephalopathy, Progressive Multifocal; Carcinoma, Squamous Cell; Gliosarcoma; Astrocytoma; Oropharyngeal Neoplasms; Colorectal Neoplasms; Lymphopenia; Solid tumours; Urinary Bladder Neoplasms; Hypopharyngeal Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Glioblastoma; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Esophageal Neoplasms; Carcinoma, Merkel Cell; Squamous Cell Carcinoma of Head and Neck; Ovarian Neoplasms; HIV Infections Details
ASP-9801 ASP-9801 Phase 1 Clinical Astellas Pharma Inc Solid tumours; Neoplasms; Neoplasm Metastasis Details
PF-06342674 RN-168; PF-6342674; PF-06342674; ZB-168 Phase 1 Clinical Pfizer Inc Diabetes Mellitus, Type 1; Multiple Sclerosis Details
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) Phase 1 Clinical Chulalongkorn University, King Chulalongkorn Memorial Hospital Brain Neoplasms; Diffuse Intrinsic Pontine Glioma Details
GSK-3888130-B GSK-3888130-B; GSK3888130B Phase 1 Clinical Glaxosmithkline Plc Multiple Sclerosis Details
BNT-152 BNT-152 Phase 1 Clinical Biontech Se Solid tumours Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message